Summary
- Trevi Therapeutics has filed proposed terms for a $70 million IPO of its common stock.
- The firm is advancing programs led by its primary compound, nalbuphine ER.
- IPO valuation is reasonable and management expects to publish topline results for Phase 3 trials from its lead program in 1H 2020.
- This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today »
Quick Take
Trevi Therapeutics (TRVI) intends to raise $70.0 million from the sale of common stock in an IPO, per an amended registration statement.
The company is advancing a series of treatment programs for various conditions that may be treated by its nalbuphine ER compound.
TRVI has achieved promising Phase 2 trial results and expects topline data from its Phase 3 trials in 1H 2020.
